Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains

/in

Wang, S., Chan, KW., Wei, D. et al. Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains. Nat Commun 15, 4301 (2024). https://doi.org/10.1038/s41467-024-48514-8

B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S

/in

Jacob-Dolan C, Lifton M, Powers OC, Miller J, Hachmann NP, Vu M, Surve N, Mazurek CR, Fisher JL, Rodrigues S, Patio RC, Anand T, Le Gars M, Sadoff J, Schmidt AG, Barouch DH. B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S. iScience. 2024 Apr 9;27(5):109716. doi: 10.1016/j.isci.2024.109716. PMID: 38655202; PMCID: PMC11035370.

The Climate Change Burden on Immune Health: Are Persons Living With HIV More at Risk?

/in

Woolley G, Kroll K, Hoffman K, Ward A, Corneli A, Mudrak SV, Qureshi MU, Okeke NL, Chan C, Jones AD, Tomaras GD, Reeves RK. The Climate Change Burden on Immune Health: Are Persons Living With HIV More at Risk? AIDS Res Hum Retroviruses. 2024 May 16. doi: 10.1089/AID.2024.0050. Epub ahead of print. PMID: 38753709.

Natural killer-like B cells are a distinct but infrequent innate immune cell subset modulated by SIV infection of rhesus macaques

/in

Manickam C, Upadhyay AA, Woolley G, Kroll KW, Terry K, Broedlow CA, Klatt NR, Bosinger SE, Reeves RK. Natural killer-like B cells are a distinct but infrequent innate immune cell subset modulated by SIV infection of rhesus macaques. PLoS Pathog. 2024 May 13;20(5):e1012223. doi: 10.1371/journal.ppat.1012223. PMID: 38739675; PMCID: PMC11115201.

Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial

/in

Frank I, Li SS, Grunenberg N, Overton ET, Robinson ST, Zheng H, Seaton KE, Heptinstall JR, Allen MA, Mayer KH, Culver DA, Keefer MC, Edupuganti S, Pensiero MN, Mehra VL, De Rosa SC, Morris DE, Wang S, Seaman MS, Montefiori DC, Ferrari G, Tomaras GD, Kublin JG, Corey L, Lu S; HVTN 124 Study Team. Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial. Lancet HIV. 2024 May;11(5):e285-e299. doi: 10.1016/S2352-3018(24)00036-5. PMID: 38692824.

Intersectional climate justice, health equity, and HIV

/in

Wilson SM, Woolley G, Hawn C, Hoffman K, Jones AD, Chan C, Mudrak SV, Qureshi MU, Ward A, Knippler ET, Okeke NL, Corneli A, Tomaras GD, Reeves RK. Intersectional climate justice, health equity, and HIV. Lancet HIV. 2024 May;11(5):e280-e281. doi: 10.1016/S2352-3018(24)00062-6. Epub 2024 Apr 3. PMID: 38582097.

COVID-19 vaccines: Immune correlates and clinical outcomes

/in

Mahrokhian, S. H., Tostanoski, L. H., Vidal, S. J., & Barouch, D. H. (2024). COVID-19 vaccines: Immune correlates and clinical outcomes. Human Vaccines & Immunotherapeutics, 20(1). https://doi.org/10.1080/21645515.2024.2324549

Isolation of a recombinant simian adenovirus encoding the human adenovirus G52 hexon suggests a simian origin for human adenovirus G52

/in

Pinski AN, Gan T, Lin S, Droit L, Diamond M, Barouch DH, Wang D.2024.Isolation of a recombinant simian adenovirus encoding the human adenovirus G52 hexon suggests a simian origin for human adenovirus G52. J Virol98:e00043-24.https://doi.org/10.1128/jvi.00043-24

A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope

/in

Joshi VR, Claiborne DT, Pack ML, Power KA, Newman RM, Batorsky R, Bean DJ, Goroff MS, Lingwood D, Seaman MS, Rosenberg E, Allen TM.2024.A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope. J Virol98:e01720-23.https://doi.org/10.1128/jvi.01720-23

A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines

/in

Vander Straeten A, Sarmadi M, Daristotle JL, Kanelli M, Tostanoski LH, Collins J, Pardeshi A, Han J, Varshney D, Eshaghi B, Garcia J, Forster TA, Li G, Menon N, Pyon SL, Zhang L, Jacob-Dolan C, Powers OC, Hall K, Alsaiari SK, Wolf M, Tibbitt MW, Farra R, Barouch DH, Langer R, Jaklenec A. A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines. Nat Biotechnol. 2024 Mar;42(3):510-517. doi: 10.1038/s41587-023-01774-z. Epub 2023 Apr 24. PMID: 37095347; PMCID: PMC10593912.